UP cop killed by saffron extremists was investigation officer in Akhlaq lynching case

Bengaluru, May 13: Former chief minister and senior Congress leader Siddaramaiah on Wednesday called the measures announced by Finance Minister Nirmala Sitharaman as 'disastrous' and said it is 'non-existent' in terms of benefits to poor migrants, labourers, contract employees and farmers.

"The first set of measures announced by @FinMinIndia @nsitharaman, after 8 PM speech by @narendramodi, is disastrous & non-existent in terms of benefits to poor migrants, labourers, contract employees, farmers, etc," Siddaramaiah said in a tweet.

The Congress leader said most of the intended benefits may not reach the end recipient.

This comes a day after Prime Minister Narendra Modi announced a Rs 20 lakh crore special economic package to revive the COVID-19 hit economy.

"The contribution by the government for the schemes announced are mostly notional and less of actuals and the devil lies in the detail," the Congress leader said in another tweet.

After Sitharaman announced support measures for MSMEs, Siddaramaiah said, "The credit infusion to MSMEs may help them clear dues to vendors but it is doubtful if they shall utilise the credit available to pay their labourers & to prevent job cuts. @FinMinIndia should have taken measures to pay part of the salaries to the employees in MSMEs."

Further questioning the Centre on 'ignoring the spending for boosting consumption', Siddaramaiah said, "The government is interested in capital infusion in the form of credits but totally ignorant of the actual spending that needs to be done to boost consumption. How can credit be considered as government spending?"

Siddaramaiah said the next set of measures should benefit the marginalised sections.

"Will be looking forward to next set of measures & I hope it will be something to benefit the marginalised sections. Direct benefits to the poorest sections will help them survive this pandemic. COVID-19 fight should not be another perception battle but a real one," he added in another tweet.

Sitharaman earlier announced Rs 3 lakh crore collateral-free automatic loans for businesses, including MSMEs.

Besides this, she also stated that to provide stressed MSMEs with equity support, the government will facilitate the provision of Rs 20,000 crore as subordinate debt.

Bengaluru, Mar 8: Lieutenant General Milind Hemant Thakur, Director-General of Supply and Transport Corps of the Indian Army, unveiled the renovated Animal Memorial at Agram Grounds in ASC Centre and College here on Saturday.

The animal memorial signifies the contributions of mules and horses of the Indian Army. These animals belonging to the Army Service Corps, who have rendered their services relentlessly during the war in the Himalayas, often paying the highest price of sacrificing their lives in the line of duty have been chronicled in the Memorial.

To ensure that these hoof prints do not get obliterated, on approval by the Government of India, their saga was brought to life in the form of a sculptured monument in the Equestrian Training Area of the ASC Centre and College.

This animal transport memorial has now been extended by constructing two walls supported by Roman pillars on either side.

These walls highlight the role played by the animals in the Indian Army since the British Raj. It gives details of 637 gallantry awards won by the brave muleteers, 49 battle casualties since independence, 14 gallantry awards to mules since independence and 05 military recognitions bestowed by the Chief of the Army Staff and other Army Commanders on AT units, who have been relied upon heavily to fill an important niche in the logistics networks of the Indian Army.

Gen Thakur also declared that 26 September each year has been nominated as the AT Remembrance Day as it was on this day in 1914, that 9th mule Corps, as part of the Indian Expeditionary Force, landed at Marseilles in France, to a most hearty and enthusiastic welcome by the French to support the British and allied armies in World War One.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.